Why Biohaven (BHVN) Is Down 52.0% After FDA Setback Forces R&D Overhaul [Yahoo! Finance]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
VYGLXIA (troriluzole) for spinocerebellar ataxia, prompting the company to restructure operations and R&D priorities. This regulatory setback marks a shift in Biohaven's resource allocation, with a heightened emphasis on advancing its most promising late-stage clinical programs while targeting a substantial reduction in direct R&D spending. We'll examine how the company's renewed focus on key clinical assets and cost reductions could shape Biohaven's investment narrative going forward. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is Biohaven's Investment Narrative? To be a shareholder in Biohaven today, you need to believe in the long-term value of its pipeline, not just in a single drug approval. The recent FDA rejection of VYGLXIA is a meaningful setback, shifting attention and resources toward several late-stage assets like BHV-1400, BHV-1300 and pivotal
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]Yahoo! Finance
- Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- Biohaven (NYSE:BHVN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Biohaven (NYSE:BHVN) had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 11/18/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- BHVN's page on the SEC website